Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous Page Next Page

Disadvantages

Liquid biopsies are not as sensitive as IHC or FISH for testing NTRK gene fusions [1]. If circulating DNA and RNA volume is low (e.g. when the tumour volume is low), a test failure or false negative may result. Finally, it is currently not available for routine clinical use as further development is required [2].

References

  1. Hofman P. Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology. Cancers (Basel) 2017; 9: pii: E154. doi: 110.3390/cancers9110154.
  2. Merker JD, Oxnard GR, Compton C et al. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol 2018; 36: 1631-1641.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings